Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors
{{output}}
The use of PARP inhibitors (PARPi) has profoundly changed the treatment of BRCA1/BRCA2-mutated cancers. Despite this, acquired resistance to PARPi has become a major challenge in the clinic. Hence, a more detailed understanding of the mechanisms underlying PAR... ...
